Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

Carcinoma, Non-Small-Cell Lung / drug therapy High-Throughput Nucleotide Sequencing Humans Lung Neoplasms / drug therapy Mutation Proto-Oncogene Proteins p21(ras) / genetics
Canada genomic alterations lung cancer next generation sequencing

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
22 06 2022
Historique:
received: 14 05 2022
revised: 17 06 2022
accepted: 20 06 2022
entrez: 25 7 2022
pubmed: 26 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

In advanced non-small cell lung cancer (NSCLC), patients with actionable genomic alterations may derive additional clinical benefit from targeted treatment compared to cytotoxic chemotherapy. Current guidelines recommend extensive testing with next generation sequencing (NGS) panels. We investigated the impact of using a targeted NGS panel (TruSight Tumor 15, Illumina) as reflex testing for NSCLC samples at a single institution. Molecular analysis examined 15 genes for hotspot mutation variants, including

Identifiants

DOI: 10.3390/curroncol29070352 PMID: 35877212 PMC: PMC9319994
pubmed: 35877212
pii: curroncol29070352
doi: 10.3390/curroncol29070352
pmc: PMC9319994
doi:

Substances chimiques

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4428-4437

Références

Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-12
pubmed: 33956494
J Thorac Oncol. 2018 Jul;13(7):1004-1011
pubmed: 29535011
Lung Cancer. 2021 Oct;160:127-135
pubmed: 34509095
Future Oncol. 2015;11(8):1211-21
pubmed: 25832878
J Thorac Oncol. 2019 Dec;14(12):2035-2038
pubmed: 31757371
Ann Oncol. 2015 Jul;26(7):1415-21
pubmed: 25922063
Cancer Treat Res Commun. 2022;31:100534
pubmed: 35278845
Eur Respir Rev. 2016 Mar;25(139):71-6
pubmed: 26929424
Genet Med. 2016 Feb;18(2):128-36
pubmed: 25880439
Curr Oncol. 2021 Aug 25;28(5):3268-3279
pubmed: 34449580
J Clin Oncol. 2018 Mar 20;36(9):911-919
pubmed: 29401004
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
Ann Oncol. 2019 May 1;30(5):839-844
pubmed: 30847464
Curr Oncol. 2017 Apr;24(2):103-110
pubmed: 28490924
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
JTO Clin Res Rep. 2022 May 17;3(6):100340
pubmed: 35719866
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Adv Exp Med Biol. 2016;893:43-57
pubmed: 26667338
J Thorac Oncol. 2014 Jul;9(7):947-956
pubmed: 24922009
J Thorac Oncol. 2021 Sep;16(9):1490-1500
pubmed: 33915250
Cancer. 2019 Nov 15;125(22):4043-4051
pubmed: 31390053
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377

Auteurs

Shelley Kuang (S)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Andrea S Fung (AS)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Kirstin A Perdrizet (KA)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
ORCID: 0000-0002-8746-665X

Kaitlin Chen (K)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
ORCID: 0000-0003-3911-9087

Janice J N Li (JJN)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
ORCID: 0000-0002-5700-2889

Lisa W Le (LW)

Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Michael Cabanero (M)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Ola Abu Al Karsaneh (OAA)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
Department of Basic Medical Sciences, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan.

Ming S Tsao (MS)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
ORCID: 0000-0002-9160-5405

Josh Morganstein (J)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Laura Ranich (L)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Adam C Smith (AC)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
ORCID: 0000-0001-9927-4914

Cuihong Wei (C)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Carol Cheung (C)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Frances A Shepherd (FA)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Geoffrey Liu (G)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Penelope Bradbury (P)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Prodipto Pal (P)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Joerg Schwock (J)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Adrian G Sacher (AG)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Jennifer H Law (JH)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Tracy L Stockley (TL)

Department of Laboratory Medicine & Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.
ORCID: 0000-0002-4476-9722

Natasha B Leighl (NB)

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Upfront Next Generation Sequencing in...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Upfront Next Generation Sequencing in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Upfront Next Generation Sequencing in...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Upfront Next Generation Sequencing in...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Upfront Next Generation Sequencing in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › Upfront Next Generation Sequencing in...